Janet A. Englund

This study reports neutralization titers from 355 human sera against 148 influenza strains, showing reduced neutralization of new H3N2 and H1N1 variants.

A sequencing-based neutralization assay across 78 H3N2 HA strains and 150 sera shows strain growth in 2023 tracks the fraction of sera with low titers, but not pooled-serum titers.

Sequencing-based neutralization of 91 H3N2 and H1N1 hemagglutinins against 302 human sera (27,409 titers) shows reduced titers to H3N2 subclade K and H1N1 D.3.1.1.

This study compares CD4 T-cell cytokine responses to SARS-CoV-2 mRNA vaccines in infants and adults, finding restricted cytokine production in infants and differences by vaccine type.

The paper measures how mutations in influenza HA affect function, stability, and antibody neutralization, showing epistasis enables antigenic change but cannot overcome pleiotropic costs that restrict evolutionary trajectories.

The paper quantifies neutralizing antibody responses to influenza strains using sera collected in 2024-2025 to inform vaccine-strain selection for 2025.

The paper maps how HA mutations affect neutralization by serum from different age groups, showing age-dependent antigenic effects and implications for viral evolution.

SwabExpress is a simplified COVID-19 testing protocol that eliminates the need for transport media and nucleic acid extraction, achieving high sensitivity and specificity.